Difference between revisions of "Enoxaparin (Lovenox)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Drug index" to "Category:Drugs")
m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA")
Line 28: Line 28:
 
[[Category:Venous thromboembolism (VTE) medications]]
 
[[Category:Venous thromboembolism (VTE) medications]]
  
[[Category:Drugs FDA approved in 1993]]
+
[[Category:FDA approved in 1993]]

Revision as of 18:54, 30 July 2018

General information

Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.[1][2][3]
Route: SC
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

History of changes in FDA indication

  • 3/29/1993: Initial FDA approval: prevention of DVT following hip replacement

Also known as

  • Brand names: Axoparin, Cardinex, Clexan, Clexane, Clotinex, Cnoxane, Cutenox, Dutenox, Enclex, Enox, Enxoaealth, Enoxol, Eparin, Lmwx, Lovenox, Markparin, Microparin, Noxprin, Pariparin, Xaparin

References